BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32690723)

  • 1. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
    Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
    Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
    Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
    Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
    Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
    Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
    Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
    Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
    Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
    Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
    Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
    Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution.
    Ballhausen A; Przybilla MJ; Jendrusch M; Haupt S; Pfaffendorf E; Seidler F; Witt J; Hernandez Sanchez A; Urban K; Draxlbauer M; Krausert S; Ahadova A; Kalteis MS; Pfuderer PL; Heid D; Stichel D; Gebert J; Bonsack M; Schott S; Bläker H; Seppälä T; Mecklin JP; Ten Broeke S; Nielsen M; Heuveline V; Krzykalla J; Benner A; Riemer AB; von Knebel Doeberitz M; Kloor M
    Nat Commun; 2020 Sep; 11(1):4740. PubMed ID: 32958755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
    Bauer K; Nelius N; Reuschenbach M; Koch M; Weitz J; Steinert G; Kopitz J; Beckhove P; Tariverdian M; von Knebel Doeberitz M; Kloor M
    Cancer Immunol Immunother; 2013 Jan; 62(1):27-37. PubMed ID: 22729559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening.
    Zhang J; Shen L; Johnston SA
    Sci Rep; 2018 Nov; 8(1):17366. PubMed ID: 30478295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
    Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
    Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Immune Biology of Microsatellite-Unstable Cancer.
    Kloor M; von Knebel Doeberitz M
    Trends Cancer; 2016 Mar; 2(3):121-133. PubMed ID: 28741532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
    Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
    Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].
    Kloor M
    Pathologe; 2013 Nov; 34 Suppl 2():277-81. PubMed ID: 24196629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes.
    Garbe Y; Maletzki C; Linnebacher M
    PLoS One; 2011; 6(11):e26517. PubMed ID: 22110587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors.
    Roudko V; Bozkus CC; Orfanelli T; McClain CB; Carr C; O'Donnell T; Chakraborty L; Samstein R; Huang KL; Blank SV; Greenbaum B; Bhardwaj N
    Cell; 2020 Dec; 183(6):1634-1649.e17. PubMed ID: 33259803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO).
    Linnebacher M; Wienck A; Boeck I; Klar E
    J Biomed Biotechnol; 2010; 2010():841451. PubMed ID: 20339516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
    D'Alise AM; Leoni G; Cotugno G; Siani L; Vitale R; Ruzza V; Garzia I; Antonucci L; Micarelli E; Venafra V; Gogov S; Capone A; Runswick S; Martin-Liberal J; Calvo E; Moreno V; Symeonides SN; Scarselli E; Bechter O
    Clin Cancer Res; 2024 Jun; 30(11):2412-2423. PubMed ID: 38506710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.